bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Materials and Methods, Supplementary Figure 1-8 from Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers
Authors: Duranti Claudia , Iorio Jessica , Lottini Tiziano , Lastraioli Elena , Crescioli Silvia , Bagni Giacomo , Lulli Matteo , Capitani Chiara , Bouazzi Rayhana , Stefanini Matteo , Carraresi Laura , Iamele Luisa , De Jonge Hugo , Arcangeli Annarosa
Published: April 2023

Supplementary Table S1 shows nucleotide sequence of the scDb-hERG1-β1. Supplementary Table S2 reports a list of primers. Supplementary Figure S1 dot blot and Coomassie staining of different scDb-hERG1-β1 clones. Supplementary Figure S2 shows peptide ELISA assay performed using different peptides. Supplementary Figure S3 shows Figure S3 cell ELISA assay performed using different cancer cell lines. Supplementary Figure S4 shows dose-dependence curves of different cell lines treated with scDb-hERG1-β1. Supplementary Figure S5 shows cell cycle plots. Supplementary Figure S6 shows spheroid growth curves of different cancer cell lines. Supplementary Figure S7 shows microscopic appearance of spheroids of PANC-1, HCT116 and MIAPaca 2 cells. Supplementary Figure S8 shows sequence alignments
Supplementary Figure from Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer
Authors: Huang Kuan-Chun , Chandra Dinesh , McGrath Shannon , Dixit Vaishali , Zhang Chi , Wu Jiayi , Tendyke Karen , Yao Huilan , Hukkanen Renee , Taylor Noel , Verbel David , Kim Dae-Shik , Endo Atsushi , Noland Thomas A. , Chen Yu , Matijevic Mark , Wang John , Hutz Janna , Sarwar Nadeem , Fang Francis G. , Bao Xingfeng
Published: April 2023

Supplementary Figure from Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer
Figure S9 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

COMPUSYN analyses cisplatin and paclitaxel
Figure S7 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

COMPUSYN analyses doxorubicin and cyclophosphamide
Figure S5 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

Drug application scheme for drug combination determination
Supplementary Data from Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis
Authors: Chandler Christopher S. , Bell Meghan M. , Chung Sebastian K. , Veach Darren R. , Fung Edward K. , Punzalan Blesida , Burnes Vargas Daniela , Patel Mitesh , Xu Hong , Guo Hong-fen , Santich Brian H. , Zanzonico Pat B. , Monette Sébastien , Nash Garrett M. , Cercek Andrea , Jungbluth Achim , Pandit-Taskar Neeta , Cheung Nai Kong V. , Larson Steven M. , Cheal Sarah M.
Published: April 2023

Supplementary Data
Figure S4 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

Drug perfusion scenario
Figure S1 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

Simulation of drug diffusion profiles
Supplementary Table from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Authors: Awasthi Niranjan , Schwarz Margaret A. , Zhang Changhua , Klinz Stephan G. , Meyer-Losic Florence , Beaufils Benjamin , Thiagalingam Arunthathi , Schwarz Roderich E.
Published: April 2023

Supplementary Table from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Authors: Awasthi Niranjan , Schwarz Margaret A. , Zhang Changhua , Klinz Stephan G. , Meyer-Losic Florence , Beaufils Benjamin , Thiagalingam Arunthathi , Schwarz Roderich E.
Published: April 2023

Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Supplementary Figure S2 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells
Authors: Fujimura Takaaki , Yamashita-Kashima Yoriko , Kawasaki Natsumi , Yoshiura Shigeki , Harada Naoki , Yoshimura Yasushi
Published: April 2023

Cell growth inhibition assay for each chemotherapeutic agent.
Supplementary Figure S1 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells
Authors: Fujimura Takaaki , Yamashita-Kashima Yoriko , Kawasaki Natsumi , Yoshiura Shigeki , Harada Naoki , Yoshimura Yasushi
Published: April 2023

CD20 expression levels in SU-DHL-4 cells and each resistant clone.
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Figure 1. ARID1A sequencing in OCI cells.
Supplementary Table S1 from Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress
Authors: Lindemann Antje , Patel Ameeta A. , Tang Lin , Tanaka Noriaki , Gleber-Netto Frederico O. , Bartels Mason D. , Wang Li , McGrail Daniel J. , Lin Shiaw-Yih , Frank Steven J. , Frederick Mitchell J. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Supplementary Table S1
Supplementary Materials and Methods from Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress
Authors: Lindemann Antje , Patel Ameeta A. , Tang Lin , Tanaka Noriaki , Gleber-Netto Frederico O. , Bartels Mason D. , Wang Li , McGrail Daniel J. , Lin Shiaw-Yih , Frank Steven J. , Frederick Mitchell J. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Supplementary Materials and Methods
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Figure 3. Individual dsiRNA knockdown targeting BRD2 and BRD3 in OCI-C5x cells.
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Figure 5. Combination drug screens with or without IC30 of CPI203 in OCI-C5x and RMG1 cells.
Supplementary Figure S7 & Supplementary S7 Legend from Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress
Authors: Lindemann Antje , Patel Ameeta A. , Tang Lin , Tanaka Noriaki , Gleber-Netto Frederico O. , Bartels Mason D. , Wang Li , McGrail Daniel J. , Lin Shiaw-Yih , Frank Steven J. , Frederick Mitchell J. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Clustering of HNSCC cell lines by DDR genes.
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Table 1. Arrayed RNAi Screen Data on Ovarian Clear Cell (OCI-C5x) and Serous (OCI-P5x)
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Table 2. The siRNA gene hits for OCI C5x and P5x.
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Table 3. IC50 at 72 hours and 7 days of BET inhibitor treatment
Supplementary Figure S5 & Supplementary S5 Legend from Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress
Authors: Lindemann Antje , Patel Ameeta A. , Tang Lin , Tanaka Noriaki , Gleber-Netto Frederico O. , Bartels Mason D. , Wang Li , McGrail Daniel J. , Lin Shiaw-Yih , Frank Steven J. , Frederick Mitchell J. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Synergy between B02 and AZD1775 is associated with impaired Rad51-mediated homologous recombination repair in HPV-positive HNSCC cells
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Table 4. The results of BET inhibitor sensitizer drug screens.
Supplementary Figure S4 & Supplementary S4 Legend from Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress
Authors: Lindemann Antje , Patel Ameeta A. , Tang Lin , Tanaka Noriaki , Gleber-Netto Frederico O. , Bartels Mason D. , Wang Li , McGrail Daniel J. , Lin Shiaw-Yih , Frank Steven J. , Frederick Mitchell J. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Combined inhibition or Rad51 and Wee1 enhances the DNA damage response in HPV-positive HNSCC cells
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Table 6. Information of antibodies used in this study.
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
Authors: Doerner Johannes , Sallard Erwan , Zhang Wenli , Solanki Manish , Liu Jing , Ehrke-Schulz Eric , Zirngibl Hubert , Lieber André , Ehrhardt Anja
Published: April 2023

Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
Supplementary Figure from Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway
Authors: Hong Jian-Hua , Tong Zhen-Jie , Wei Tung-En , Lu Yu-Chuan , Huang Cheng-Yu , Huang Chao-Yuan , Chiang Chih-Hung , Jaw Fu-Shan , Cheng Hsiao-Wei , Wang Hsiang-Tsui
Published: April 2023

Supplementary Figure from Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway
Supplementary Data from Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53
Authors: Li Junhui , Lama Rati , Galster Samuel L. , Inigo Joseph R. , Wu Jin , Chandra Dhyan , Chemler Sherry R. , Wang Xinjiang
Published: April 2023

Supplementary Data from Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
Authors: Doerner Johannes , Sallard Erwan , Zhang Wenli , Solanki Manish , Liu Jing , Ehrke-Schulz Eric , Zirngibl Hubert , Lieber André , Ehrhardt Anja
Published: April 2023

Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
Supplementary Figure S3 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19
Authors: Tokunaga Yoshihiro , Sasaki Takahiro , Goto Shunsuke , Adachi Keishi , Sakoda Yukimi , Tamada Koji
Published: April 2023

Supplementary Figure S3 shows infiltration of immune cells in the tumor tissues after treatment with P1A-T cells with anti-PD-1 mAb.
Supplementary Figure from HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models
Authors: Gómez Valentí , Galazi Myria , Weitsman Gregory , Monypenny James , Al-Salemee Fahad , Barber Paul R. , Ng Kenrick , Beatson Richard , Szokol Bálint , Orfi László , Mullen Greg , Vanhaesebroeck Bart , Chowdhury Simon , Leung Hing Y. , Ng Tony
Published: April 2023

Supplementary Figure from HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models
Supplementary Figure S1 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19
Authors: Tokunaga Yoshihiro , Sasaki Takahiro , Goto Shunsuke , Adachi Keishi , Sakoda Yukimi , Tamada Koji
Published: April 2023

Supplementary Figure S1 shows an indispensable role of tumor specificity of TCR in the anti-tumor efficacy of IL-7/ CCL19-producing T cells.
Supplementary Table S3 from SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents
Authors: Gartrell Jessica , Mellado-Largarde Marcia , Clay Michael R. , Bahrami Armita , Sahr Natasha A. , Sykes April , Blankenship Kaley , Hoffmann Lauren , Xie Jia , Cho Hyekyung P. , Twarog Nathaniel , Connelly Michele , Yan Koon-Kiu , Yu Jiyang , Porter Shaina N. , Pruett-Miller Shondra M. , Neale Geoffrey , Tinkle Christopher L. , Federico Sara M. , Stewart Elizabeth A. , Shelat Anang A.
Published: April 2023

Supplementary Table S3
Supplementary Table S1 from SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents
Authors: Gartrell Jessica , Mellado-Largarde Marcia , Clay Michael R. , Bahrami Armita , Sahr Natasha A. , Sykes April , Blankenship Kaley , Hoffmann Lauren , Xie Jia , Cho Hyekyung P. , Twarog Nathaniel , Connelly Michele , Yan Koon-Kiu , Yu Jiyang , Porter Shaina N. , Pruett-Miller Shondra M. , Neale Geoffrey , Tinkle Christopher L. , Federico Sara M. , Stewart Elizabeth A. , Shelat Anang A.
Published: April 2023

Supplementary Table S1
Supplementary Figure from Inhibition of Oxidized Nucleotide Sanitation By TH1579 and Conventional Chemotherapy Cooperatively Enhance Oxidative DNA Damage and Survival in AML
Authors: Centio Anders , Estruch Montserrat , Reckzeh Kristian , Sanjiv Kumar , Vittori Camilla , Engelhard Sophia , Warpman Berglund Ulrika , Helleday Thomas , Theilgaard-Mönch Kim
Published: April 2023

Supplementary Figure from Inhibition of Oxidized Nucleotide Sanitation By TH1579 and Conventional Chemotherapy Cooperatively Enhance Oxidative DNA Damage and Survival in AML
Supplementary Figure from Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors
Authors: Yamamoto Tomomi M. , Webb Patricia G. , Davis Dana M. , Baumgartner Heidi K. , Woodruff Elizabeth R. , Guntupalli Saketh R. , Neville Margaret , Behbakht Kian , Bitler Benjamin G.
Published: April 2023

Supplementary Figure from Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors
Supplementary Table from A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies
Authors: Zimmermann Astrid , Zenke Frank T. , Chiu Li-Ya , Dahmen Heike , Pehl Ulrich , Fuchss Thomas , Grombacher Thomas , Blume Beatrix , Vassilev Lyubomir T. , Blaukat Andree
Published: April 2023

Supplementary Table from A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies
Supplementary Tables from Targeting Tumor–Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer
Authors: Dosch Austin R. , Singh Samara , Dai Xizi , Mehra Siddharth , Silva Iago De Castro , Bianchi Anna , Srinivasan Supriya , Gao Zhen , Ban Yuguang , Chen Xi , Banerjee Sulagna , Nagathihalli Nagaraj S. , Datta Jashodeep , Merchant Nipun B.
Published: April 2023

Supplementary Tables
Supplementary Fig S8 from Heme Sequestration as an Effective Strategy for the Suppression of Tumor Growth and Progression
Authors: Wang Tianyuan , Ashrafi Adnin , Konduri Purna Chaitanya , Ghosh Poorva , Dey Sanchareeka , Modareszadeh Parsa , Salamat Narges , Alemi Parinaz Sadat , Berisha Eranda , Zhang Li
Published: April 2023

Figure S8. A, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of ï�¢-actin in control and HeSP2- or HeSP2del-treated tumors. B, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of GAPDHï€ in control and HeSP2- or HeSP2del-treated tumors. C, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of TOM20 in control and HeSP2- or HeSP2del-treated tumors. D, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of VDAC in control and HeSP2- or HeSP2del-treated tumors. Protein levels were quantified. Data were plotted as mean {plus minus} SEM. E, Representative 10X IHC images of H1299 NSCLC tumor tissue sections showing the levels of VEGFR1 in control and HeSP-treated tumors. F, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of VEGFA in control and HeSP-treated tumors. Shown IHC figures are montages or 10X images of control and HeSP-treated tumor tissue sections stained with DAPI or antibodies against the indicated protein. The white rectangles in DAPI images denote the regions shown in 10X images. Scale bar: montage, 1 mm; 10X, 200 Î¼m. Protein levels were quantified, and data were plotted as mean {plus minus} SEM. ***, P < 0.005. G, Representative 40X IHC images of H1299 NSCLC tumor tissue sections showing CD31 staining in control and HeSP-treated tumors. H, Representative 40X IHC images of H1299 NSCLC tumor tissue sections showing CD34 staining in control and HeSP-treated tumors. Scale bar, 50Âµm.
Supplementary Fig S5 from Heme Sequestration as an Effective Strategy for the Suppression of Tumor Growth and Progression
Authors: Wang Tianyuan , Ashrafi Adnin , Konduri Purna Chaitanya , Ghosh Poorva , Dey Sanchareeka , Modareszadeh Parsa , Salamat Narges , Alemi Parinaz Sadat , Berisha Eranda , Zhang Li
Published: April 2023

Figure S5. HeSP treatment effectively inhibits transporters and key enzymes in glucose and glutamine metabolism in subcutaneous NSCLC tumor xenografts. A, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of SLC2A1 in control and HeSP-treated tumors. B, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of HK2 in control and HeSP-treated tumors. C, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of SLC1A5 in control and HeSP-treated tumors. D, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of GLS in control and HeSP-treated tumors. Shown are montages and 10X images of control and HeSP-treated tumor tissue sections stained with DAPI (row 1) or antibodies against the indicated protein (row 2) or merged images of DAPI and the indicated protein (row 3). The white rectangles in DAPI images denote the regions shown in 10X images. Scale bar, montage, 1 mm; 10X, 200 Î¼m. Protein levels were quantified, and data were plotted as mean {plus minus} SEM. ***, P < 0.005.
Supplementary Figure from A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies
Authors: Zimmermann Astrid , Zenke Frank T. , Chiu Li-Ya , Dahmen Heike , Pehl Ulrich , Fuchss Thomas , Grombacher Thomas , Blume Beatrix , Vassilev Lyubomir T. , Blaukat Andree
Published: April 2023

Supplementary Figure from A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies
Supplementary Fig S3 from Heme Sequestration as an Effective Strategy for the Suppression of Tumor Growth and Progression
Authors: Wang Tianyuan , Ashrafi Adnin , Konduri Purna Chaitanya , Ghosh Poorva , Dey Sanchareeka , Modareszadeh Parsa , Salamat Narges , Alemi Parinaz Sadat , Berisha Eranda , Zhang Li
Published: April 2023

Figure S3. HeSPs effectively suppress the growth, oxygen consumption rates (OCRs), and ATP generation in subcutaneous A549-luc NSCLC tumor xenografts and HeSPs do not cause significant toxic effects on mouse liver and blood. A, Photos showing excised tumors from NOD/SCID mice treated with saline (control) or HeSPs (25 mg/kg I.V. every 3 days) for 3 weeks (n = 5/group). B, Average masses for control and treated tumors shown. C, The time course of tumor volumes in control and mice treated with HeSPs. Tumor volumes were calculated weekly using Caliper measurements and are shown here. D, Average body masses of control and treated mice bearing tumors. E, Oxygen consumption rates (OCRs) measured in cells from control and treated tumors. F, ATP levels measured in cells from control and treated tumors. G, Average serum ALT (alanine transaminase) levels in mice bearing subcutaneous lung tumor xenografts treated with or without HeSPs. H, Relative liver ATP levels in live cells from mice bearing subcutaneous lung tumor xenografts treated with or without HeSPs. I, Average red blood cell counts in mice bearing subcutaneous lung tumor xenografts treated with or without HeSPs. J, Average hemoglobin levels in mice bearing subcutaneous lung tumor xenografts treated with or without HeSPs. Data were plotted as mean {plus minus} SEM. *, P <â€‰0.05; **, P < 0.01; ***, P < 0.005.
Supplementary Fig S2 from Heme Sequestration as an Effective Strategy for the Suppression of Tumor Growth and Progression
Authors: Wang Tianyuan , Ashrafi Adnin , Konduri Purna Chaitanya , Ghosh Poorva , Dey Sanchareeka , Modareszadeh Parsa , Salamat Narges , Alemi Parinaz Sadat , Berisha Eranda , Zhang Li
Published: April 2023

Figure S2. HeSPs inhibit heme uptake and inhibit NSCLC cell proliferation in a dose-dependent manner. The effects of HeSPs on heme uptake in H1299 (A) and A549 (B) NSCLC cells are shown. Cells were treated with 60 Î¼mol/L ZnPP in the presence or the absence of 40 Î¼mol/L HeSPs. C & D, Data from representative NSCLC cell lines H1299 (C), and A549 (D) are shown. Cells were treated with the indicated concentration (Î¼M) of HeSP in medium. Data were plotted as mean {plus minus} SD. *, P <â€‰0.05; **, P < 0.01; ***, P < 0.005. E & F, HeSPs induce apoptosis in H1299 (E) and A549 (F) NSCLC cells, and addition of equimolar concentration of heme to HeSP-treated cells largely reverses the apoptosis. Cells were subjected to apoptosis assay with Annexin V-FITC and Propidium Iodide (PI) staining. The images of cells were captured with bright field microscopy (BF) or fluorescent microscopy with a GFP or Texas Red (for PI) filter. Scale bar, 200â€‰âµm.
Supplementary Fig S1 from Heme Sequestration as an Effective Strategy for the Suppression of Tumor Growth and Progression
Authors: Wang Tianyuan , Ashrafi Adnin , Konduri Purna Chaitanya , Ghosh Poorva , Dey Sanchareeka , Modareszadeh Parsa , Salamat Narges , Alemi Parinaz Sadat , Berisha Eranda , Zhang Li
Published: April 2023

Figure S1. HasAyp does not suppress NSCLC tumor growth significantly and HeSPs bind to heme strongly. A, Images showing resected tumors from mice implanted with subcutaneous xenografts (H1299-luc cells) treated with saline (control) or HasAyp. Average masses for control and HasAyp-treated tumors (n = 4/group). Data were plotted as mean {plus minus} SD. B, The pull-down of HasAyp and HeSP2 by heme agarose beads. 500 picomoles of human serum albumin (HSA, positive control), carbonic anhydrase (CA, negative control), HasAyp, and HeSP2 were incubated with heme-agarose beads, respectively. The input (In) proteins, bound (Bu), and unbound proteins (UnB) were analyzed by SDS-PAGE and shown. C, Estimated heme levels from the staining of heme in the Hb and HeSP2 bands in Figure 2G. D, The transfer of heme from hemoglobin (Hb) to HeSP2 is instantaneous. Hemoglobin (Hb), apo-HeSP2, and mixtures of Hb and apo-HeSP2 were incubated for the increasing times and then analyzed on native PAGE, followed by staining for protein and heme, respectively. Lane 1, 20 Î¼M Hb; lane 2, 200 Î¼M HeSP2; lane 3, 200 Î¼M HeSP2+ 200 Î¼M Heme; lanes 4-9, 20 Î¼M Hb + 200 Î¼M HeSP2 incubated for 1, 2, 5, 10, 20, and 30 minutes, respectively. E, Detection of heme transfer from hemoglobin (Hb) to HasAyp. Hemoglobin (Hb), apo- HasAyp, and mixtures of Hb and HasAyp were analyzed on native PAGE and stained for protein and heme, respectively. Lane 1, 20 Î¼M Hb; lane 2, 200 Î¼M HasAyp; lane 3, 200 Î¼M HasAyp + 200 Î¼M Heme; lane 4, 20 Î¼M Hb + 20 Î¼M HasAyp; lane 5, 20 Î¼M Hb + 50 Î¼M HasAyp; lane 6, 20 Î¼M Hb + 100 Î¼M HasAyp; lane 7, 20 Î¼M Hb + 200 Î¼M HasAyp. F, Estimated heme levels from the staining of heme in the Hb and HasAyp bands in E. G, The pull-down of various HeSPs by heme agarose beads. 500 picomoles of indicated HeSPs were incubated with heme-agarose beads. The input (In) proteins, bound (Bu) and unbound proteins (UnB) were analyzed by SDS-PAGE and shown. H, The effects of HeSPs on heme absorption spectra. line 1: 5 Î¼M heme, line 2: 5 Î¼M heme + 10 Î¼M HeSP, line 3: 10 Î¼M HeSP. I, Elution profiles of heme-HeSP mixtures on Sephadex-G50 columns. line1: 0.25 mM heme + 0.25 mM HeSP (protein absorption at 280 nm), line2: 0.25 mM heme + 0.25 mM HeSP (heme absorption at 400 nm), line 3: 0.25 mM (heme absorption at 400 nm).
Supplementary Data from Frondoside A Inhibits an MYC-Driven Medulloblastoma Model Derived from Human-Induced Pluripotent Stem Cells
Authors: Xue Yingchao , Fu Yi , Zhao Fenghong , Gui Gege , Li Yuguo , Rivero-Hinojosa Samuel , Liu Guanshu , Li Yunqing , Xia Shuli , Eberhart Charles G. , Ying Mingyao
Published: April 2023

Fig. S1, S2, S3 and Table S1.
Supplementary Table from [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B–targeted Therapy in Triple-negative Breast Cancer
Authors: Lee Supum , Cavaliere Alessandra , Gallezot Jean-Dominique , Keler Tibor , Michelhaugh Sharon K. , Belitzky Erika , Liu Michael , Mulnix Tim , Maher Stephen E. , Bothwell Alfred L.M. , Li Fangyong , Phadke Manali , Mittal Sandeep , Marquez-Nostra Bernadette
Published: April 2023

Supplementary Table from [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B–targeted Therapy in Triple-negative Breast Cancer
Supplementary Figure from [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B–targeted Therapy in Triple-negative Breast Cancer
Authors: Lee Supum , Cavaliere Alessandra , Gallezot Jean-Dominique , Keler Tibor , Michelhaugh Sharon K. , Belitzky Erika , Liu Michael , Mulnix Tim , Maher Stephen E. , Bothwell Alfred L.M. , Li Fangyong , Phadke Manali , Mittal Sandeep , Marquez-Nostra Bernadette
Published: April 2023

Supplementary Figure from [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B–targeted Therapy in Triple-negative Breast Cancer
Supplementary Data from The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases
Authors: Anastasia Alessia , Dellavedova Giulia , Ramos-Montoya Antonio , James Neil , Chiorino Giovanna , Russo Massimo , Baakza Hana , Wilson Joanne , Ghilardi Carmen , Cadogan Elaine B. , Giavazzi Raffaella , Bani Maria Rosa
Published: April 2023

Supplementary Data from The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases
Supplementary Table 6 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

Overlap between RNAseq datasets from MDA-MB-453 AR-High cells and HCI-009 PDX mice treated with Sevi
Supplementary Table 5 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

Cell cycle gene expression differences between AR-High versus AR-Low MDA-MB-453
Supplementary Table from Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma
Authors: Javaid Sehrish , Schaefer Antje , Goodwin Craig M. , Nguyen Victoria V. , Massey Frances L. , Pierobon Mariaelena , Gambrell-Sanders Da'Jhnae , Waters Andrew M. , Lambert Kathryn N. , Diehl J. Nathaniel , Hobbs G. Aaron , Wood Kris C. , Petricoin Emanuel F. , Der Channing J. , Cox Adrienne D.
Published: April 2023

Supplementary Table from Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma
Supplementary Table 2 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

Gene expression change following Sevi treatment in HCI-009 PDXs
Supplementary Table from Variable Mutation Expression in Human Cancers: A “Hide-and-Seek” Mechanism Linked to Differential MHC-I Presentation Dynamics
Authors: Boichard Amélie , Kurzrock Razelle
Published: April 2023

Supplementary Table from Variable Mutation Expression in Human Cancers: A “Hide-and-Seek” Mechanism Linked to Differential MHC-I Presentation Dynamics
Supplementary Figure from Variable Mutation Expression in Human Cancers: A “Hide-and-Seek” Mechanism Linked to Differential MHC-I Presentation Dynamics
Authors: Boichard Amélie , Kurzrock Razelle
Published: April 2023

Supplementary Figure from Variable Mutation Expression in Human Cancers: A “Hide-and-Seek” Mechanism Linked to Differential MHC-I Presentation Dynamics
Supplementary Figure 2 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

HCI-009 PDX experimental principal component analyses. (A-B) RNAseq principal component analyses (PC) for HCI-009 PDX experiments. (A) HCI-009 PDX tumor portions were injected into the mammary fat pads of female NSG mice supplemented with cellulose or DHT (dihydrotestosterone); n=5-7 mice per group. (B) HCI-009 PDX tumor portions were injected into the mammary fat pads of female NSG mice. Mice were administered vehicle or 150mg/kg/day Sevi (seviteronel); n=4-5 mice per group.
Supplementary Figures 1-7 from Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition
Authors: Carnevalli Larissa S. , Taylor Molly A. , King Matthew , Coenen-Stass Anna M.L. , Hughes Adina M. , Bell Sigourney , Proia Theresa A. , Wang Yanjun , Ramos-Montoya Antonio , Wali Neha , Carroll Danielle , Singh Maneesh , Moschetta Michele , Gutierrez Pablo Morentin , Gardelli Cristina , Critchlow Susan E. , Klinowska Teresa , Fawell Stephen E. , Barry Simon T.
Published: April 2023

Supplementary Figure 1. Pharmacokinetic (PK) properties of AZD3458 in mouse. Supplementary Figure 2. In vivo pharmacodynamic properties of AZD3458 in mouse neutrophils. Supp Fig 3. PI3K-ï�§/mTOR pathway regulates expression of IL-10/IL-12 via LPS-induced glycolytic burst. Supplementary Figure 4. AZD3458 improves checkpoint activity in CT-26 tumor models. Supplementary Figure 5. AZD3458 improves checkpoint activity in 4T1 tumor models. Supplementary Figure 6. Top canonical IPA pathways across tissues in AZD3458+PD-1 combination group. Supplementary Figure 7. Graphical abstract.
Supplementary Data1 from BRAFV600E Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis
Authors: Wang Chan-Juan , Cui Lei , Ma Hong-Hao , Wang Dong , Zhang Li , Lian Hong-Yun , Li Wei-Jing , Zhang Qing , Wang Tian-You , Li Zhi-Gang , Zhang Rui
Published: April 2023

Comparison of clinical characteristics of our cohort and other two cohorts
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
Authors: Piovesan Dana , Tan Joanne B.L. , Becker Annette , Banuelos Jesus , Narasappa Nell , DiRenzo Daniel , Zhang Kristen , Chen Ada , Ginn Elaine , Udyavar Akshata R. , Yin Fangfang , Paprcka Susan L. , Purandare Bhamini , Park Timothy W. , Kimura Nikki , Kalisiak Jaroslaw , Young Stephen W. , Powers Jay P. , Schindler Uli , Sivick Kelsey E. , Walters Matthew J.
Published: April 2023

Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
Supplementary Methods from Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
Authors: Garcia Natalia , Del Pozo Vanessa , Yohe Marielle E. , Goodwin Craig M. , Shackleford Terry J. , Wang Long , Baxi Kunal , Chen Yidong , Rogojina Anna T. , Zimmerman Sara M. , Peer Cody J. , Figg William D. , Ignatius Myron S. , Wood Kris C. , Houghton Peter J. , Vaseva Angelina V.
Published: April 2023

Supplementary Methods
Supplementary Figures from Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
Authors: Garcia Natalia , Del Pozo Vanessa , Yohe Marielle E. , Goodwin Craig M. , Shackleford Terry J. , Wang Long , Baxi Kunal , Chen Yidong , Rogojina Anna T. , Zimmerman Sara M. , Peer Cody J. , Figg William D. , Ignatius Myron S. , Wood Kris C. , Houghton Peter J. , Vaseva Angelina V.
Published: April 2023

Supplementary figures and legends
Supplementary Data from The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner
Authors: Arnold Carina , Demuth Philipp , Seiwert Nina , Wittmann Simon , Boengler Kerstin , Rasenberger Birgit , Christmann Markus , Huber Magdalena , Brunner Thomas , Linnebacher Michael , Fahrer Jörg
Published: April 2023

contains supplementary figures and tables
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Authors: Rao Thapi D. , Xu Mengyao , Eng Stephanie , Yang Guangli , Manson Robin , Rosales Nestor , Kumar Raj , Veillard Irva E. , Zhou Qin , Iasonos Alexia , Ouerfelli Ouathek , Djaballah Hakim , Spriggs David R. , Yeku Oladapo O.
Published: April 2023

Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figures from The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity In Vitro and In Vivo
Authors: Klausz Katja , Kellner Christian , Gehlert Carina Lynn , Krohn Steffen , Wilcken Hauke , Floerkemeier Inken , Günther Andreas , Bauerschlag Dirk O. , Clement Bernd , Gramatzki Martin , Peipp Matthias
Published: April 2023

Supplementary Figures 1-2
Supplementary Data from Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
Authors: Zammarchi Francesca , Havenith Karin EG. , Chivers Simon , Hogg Paul , Bertelli Francois , Tyrer Peter , Janghra Narinder , Reinert Halla W. , Hartley John A. , van Berkel Patrick H.
Published: April 2023

Supplementary Data from Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
Table S4 from New Insights Into Platelet-enriched miRNAs: Production, Functions, Roles in Tumors, and Potential Targets for Tumor Diagnosis and Treatment
Authors: Miao Shuo , Zhang Qingsong , Chang Wenguang , Wang Jianxun
Published: April 2023

Platelet miRNAs and their roles in platelet production.
Table S3 from New Insights Into Platelet-enriched miRNAs: Production, Functions, Roles in Tumors, and Potential Targets for Tumor Diagnosis and Treatment
Authors: Miao Shuo , Zhang Qingsong , Chang Wenguang , Wang Jianxun
Published: April 2023

Potential platelet miRNAs are involved in tumor regulation by regulating platelets.
Table S2 from New Insights Into Platelet-enriched miRNAs: Production, Functions, Roles in Tumors, and Potential Targets for Tumor Diagnosis and Treatment
Authors: Miao Shuo , Zhang Qingsong , Chang Wenguang , Wang Jianxun
Published: April 2023

Overview of platelet miRNAs and their functions within platelets.
Supplementary Table S1 from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow
Authors: Zhang Chao , Xu Xiaoxuan , Trotter Timothy N. , Gowda Pramod S. , Lu Yun , Suto Mark J. , Javed Amjad , Murphy-Ullrich Joanne E. , Li Juan , Yang Yang
Published: April 2023

Supplementary Table S1
Supplementary Table S1 shows the company's name and the product numbers of Bortezomib, 5-Fluorouracil and Gemcitabine as well as the company's name and the product numbers of all antibodies listed in table S1, which we purchased and used for this study.
Table S1 from New Insights Into Platelet-enriched miRNAs: Production, Functions, Roles in Tumors, and Potential Targets for Tumor Diagnosis and Treatment
Authors: Miao Shuo , Zhang Qingsong , Chang Wenguang , Wang Jianxun
Published: April 2023

The characteristics of the most abundant miRNAs in platelets as described in different reports.
Figure S1 from New Insights Into Platelet-enriched miRNAs: Production, Functions, Roles in Tumors, and Potential Targets for Tumor Diagnosis and Treatment
Authors: Miao Shuo , Zhang Qingsong , Chang Wenguang , Wang Jianxun
Published: April 2023

The process of platelet production. In bone marrow, all hematopoietic progenitors are derived from hematopoietic stem cells (HSCs). Platelets gradually differentiate from HSCs. HSCs first differentiate into the common myeloid progenitor cells (CMPs) and common lymphoid progenitor cells (CLPs). CMPs further differentiate into granulocyte/macrophage progenitor cells (GMPs) and megakaryocyte-erythrocyte progenitor cells (MEPs). MEPs then differentiate into MK precursor cells and red blood cells. MK precursor cells need to go through a maturation process before shedding platelets. In this process, although the ability to divide is lost, DNA replication and cytoplasmic maturation (including the rearrangement of the cytoplasmic skeleton and the formation of pseudopodia) are maintained. After maturation, MKs are arranged adjacent to vascular endothelial cells, forming platelet precursors and releasing platelets into circulation.
Supplementary Methods from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow
Authors: Zhang Chao , Xu Xiaoxuan , Trotter Timothy N. , Gowda Pramod S. , Lu Yun , Suto Mark J. , Javed Amjad , Murphy-Ullrich Joanne E. , Li Juan , Yang Yang
Published: April 2023

Supplementary Methods
Supplementary Methods descript detailed methods of Bioluminescence imaging, ELISA, Flow cytometry, Isolation and culture of Pre-OBs with 5TGM1-Luc MM cells, Generation and sorting of MDSCs, Cell proliferation assays, Treatment of MM cells with OB-Runx2+/+ and OB-Runx2-/- BMS in vitro, and Western blotting.
Supplementary Figure from Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability
Authors: Gilbert Sophie , Péant Benjamin , Malaquin Nicolas , Tu Véronique , Fleury Hubert , Leclerc-Desaulniers Kim , Rodier Francis , Mes-Masson Anne-Marie , Saad Fred
Published: April 2023

Supplementary Figure from Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability
Supplementary Data from Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models
Authors: Schmidt Keith T. , Chau Cindy H. , Strope Jonathan D. , Huitema Alwin D.R. , Sissung Tristan M. , Price Douglas K. , Figg William D.
Published: April 2023

Figures S1, S2, S3, S4, and S5
Supplementary Data from Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability
Authors: Gilbert Sophie , Péant Benjamin , Malaquin Nicolas , Tu Véronique , Fleury Hubert , Leclerc-Desaulniers Kim , Rodier Francis , Mes-Masson Anne-Marie , Saad Fred
Published: April 2023

Supplementary Data from Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability
Supplementary Figure from B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model
Authors: Zhang Shihong , Black R. Graeme , Kohli Karan , Hayes Brian J. , Miller Cassandra , Koehne Amanda , Schroeder Brett A. , Abrams Kraig , Schulte Brian C. , Alexiev Borislav A. , Heimberger Amy B. , Zhang Ali , Jing Weiqing , Ng Juliana Chi Kei , Shinglot Himaly , Seguin Bernard , Salter Alexander I. , Riddell Stanley R. , Jensen Michael C. , Gottschalk Stephen , Moore Peter F. , Torok-Storb Beverly , Pollack Seth M.
Published: April 2023

Supplementary Figure from B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model
Figure from Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid–coated Layer-by-Layer Nanoparticles
Authors: Tošić Isidora , Heppler Lisa N. , Egusquiaguirre Susana P. , Boehnke Natalie , Correa Santiago , Costa Daniel F. , Moore Elizabeth A. Grossman , Pal Sharmistha , Richardson Douglas S. , Ivanov Alexander R. , Haas-Kogan Daphne A. , Nomura Daniel K. , Hammond Paula T. , Frank David A.
Published: April 2023

Supplemental data
Supplementary Data from Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells
Authors: Lee Wen-Hsin Sandy , Ye Zhiyong , Cheung Alice M.S. , Goh Y.P. Sharon , Oh Hsueh Ling Janice , Rajarethinam Ravisankar , Yeo Siok Ping , Soh Mun Kuen , Chan Esther Hian Li , Tan Lip Kun , Tan Soo-Yong , Chuah Charles , Chng Wee Joo , Connolly John E. , Wang Cheng-I
Published: April 2023

Pathology report
Table S5 from RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Authors: Arai Hiroyuki , Cao Shu , Battaglin Francesca , Wang Jingyuan , Kawanishi Natsuko , Tokunaga Ryuma , Loupakis Fotios , Stintzing Sebastian , Soni Shivani , Zhang Wu , Mancao Christoph , Salhia Bodour , Mumenthaler Shannon M. , Cremolini Chiara , Heinemann Volker , Falcone Alfredo , Millstein Joshua , Lenz Heinz-Josef
Published: April 2023

Associations between LIN28B rs314277/rs314276 and clinical outcomes in RAS mutant type patients
Supplementary Figure from Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer
Authors: Rau Alexander , Janssen Nicole , Kühl Lennart , Sell Thomas , Kalmykova Svetlana , Mürdter Thomas E. , Dahlke Marc-H. , Sers Christine , Morkel Markus , Schwab Matthias , Kontermann Roland E. , Olayioye Monilola A.
Published: April 2023

Supplementary Figure from Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer
Table S3 from RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Authors: Arai Hiroyuki , Cao Shu , Battaglin Francesca , Wang Jingyuan , Kawanishi Natsuko , Tokunaga Ryuma , Loupakis Fotios , Stintzing Sebastian , Soni Shivani , Zhang Wu , Mancao Christoph , Salhia Bodour , Mumenthaler Shannon M. , Cremolini Chiara , Heinemann Volker , Falcone Alfredo , Millstein Joshua , Lenz Heinz-Josef
Published: April 2023

Associations between LIN28B rs314277/rs314276 and clinical outcomes
Table S2 from RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Authors: Arai Hiroyuki , Cao Shu , Battaglin Francesca , Wang Jingyuan , Kawanishi Natsuko , Tokunaga Ryuma , Loupakis Fotios , Stintzing Sebastian , Soni Shivani , Zhang Wu , Mancao Christoph , Salhia Bodour , Mumenthaler Shannon M. , Cremolini Chiara , Heinemann Volker , Falcone Alfredo , Millstein Joshua , Lenz Heinz-Josef
Published: April 2023

Results of odds ratio and hazard ratio in meta-analysis for tumor response, progression-free survival and overall survival